News Sentiment

RLAY sentiment intelligence

Relay Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 53 Balanced news tone 67 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 20.01 Week of 10 Jul 2026
Weighted tone 53/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

80/100 classification confidence.

Company focus 58

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend active

+7.3% over one week, +35.1% over four weeks, trend active, and materially above fair value.

Latest direct headline Positive

Canaccord initiates Relay Therapeutics stock with buy rating

Market Reaction

Price moving ahead of tone

62/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 80/100 classification
One-week reaction 7.3% Price confirming higher
Trend fit Trend active 35.1% over four weeks
Fair value 164.8% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 15
Neutral 41
Negative 11

Relevance

Why the article matched

Direct first
Direct company coverage 58
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Market source 10
Investing.com 7
Stock Titan 7
TradingView 6
simplywall.st 6
MT Newswires 3
GlobeNewswire 3
Moomoo 2

Event Lens

What the news is about

Classified themes
Market update 37
Earnings 16
Analyst action 9
Deals and strategy 2
Balance sheet 2
Regulatory and legal 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 67
Investing.com Direct company coverage

Canaccord initiates Relay Therapeutics stock with buy rating

Canaccord has initiated coverage on Relay Therapeutics Inc. (NASDAQ:RLAY) with a buy rating and a price target of $29.00, citing its lead asset zovegalisib. The firm believes zovegalisib, targeting mutant PI3Kα, offers improved efficacy and safety for breast cancer and vascular a

Tone
Positive 76/100
Event
Analyst action
Published
16 Jul 2026 14:11
Source
Investing.com
Moomoo Direct company coverage

CCORF Initiates Relay Therapeutics(RLAY.US) With Buy Rating, Announces Target Price $29

CCORF has initiated coverage on Relay Therapeutics (RLAY.US) with a "Buy" rating. The firm has set a target price of $29 for the company's shares. This indicates a positive outlook on Relay Therapeutics' future performance by CCORF.

Tone
Positive 75/100
Event
Analyst action
Published
16 Jul 2026 10:11
Source
Moomoo
TradingView Direct company coverage

Price to earnings forward of Relay Therapeutics, Inc. – NASDAQ:RLAY

This article provides a financial overview of Relay Therapeutics, Inc. (NASDAQ: RLAY), focusing on its forward price-to-earnings ratio. It presents the company's financial data as available on TradingView, indicating that the market was closed at the time of publication with no t

Tone
Neutral 50/100
Event
Earnings
Published
09 Jul 2026 10:10
Source
TradingView
Moomoo Direct company coverage

Relay Therapeutics Insider Sold Shares Worth $331,131, According to a Recent SEC Filing

A recent SEC filing revealed that Richard Peters, Chief Executive Officer of Relay Therapeutics, sold 30,000 shares of the company's common stock for a total of $331,131. The sale occurred at an average price of $11.0377 per share. Following this transaction, Peters still directl

Tone
Negative 40/100
Event
Market update
Published
09 Jul 2026 02:10
Source
Moomoo
GuruFocus Direct company coverage

Insider Sell Alert: Donald Bergstrom Sells Shares of Relay Thera

Donald Bergstrom, President of Research and Development at Relay Therapeutics Inc (RLAY), recently sold 8,660 company shares, reducing his holdings to 409,897 shares. This transaction is part of a trend over the last year where Bergstrom has sold 186,854 shares with no purchases,

Tone
Negative 27/100
Event
Market update
Published
09 Jul 2026 01:10
Source
GuruFocus
Stock Titan Direct company coverage

Relay Therapeutics (RLAY) R&D chief sells 8,660 shares in 10b5-1 trade

Donald A. Bergstrom, President of R&D at Relay Therapeutics (RLAY), sold 8,660 shares of common stock at a weighted average price of $18.71 per share under a pre-arranged Rule 10b5-1 trading plan. After the sale, Bergstrom still directly holds 409,897 shares, including restricted

Tone
Neutral 50/100
Event
Market update
Published
08 Jul 2026 22:10
Source
Stock Titan
Investing.com Direct company coverage

Relay Therapeutics president and CEO Sanjiv Patel sells $943,736 in stock

Sanjiv Patel, President and CEO of Relay Therapeutics (NASDAQ:RLAY), sold $943,736 worth of company stock on July 7, 2026, as part of a pre-arranged trading plan. This sale occurred while the stock was trading near its 52-week high, following a significant 450% gain over the past

Tone
Neutral 50/100
Event
Market update
Published
08 Jul 2026 21:10
Source
Investing.com
Investing.com Direct company coverage

Relay Therapeutics CFO Thomas Catinazzo sells $331,130 in stock

Relay Therapeutics CFO Thomas Catinazzo sold 17,717 shares of the company's common stock for a total of $331,130 on July 6, 2026. The sale was executed via a Rule 10b5-1 trading plan and occurred while the stock (NASDAQ: RLAY) traded near its 52-week high after a significant gain

Tone
Neutral 50/100
Event
Market update
Published
08 Jul 2026 21:10
Source
Investing.com
Investing.com Direct company coverage

Relay Therapeutics president sells $162,028 in company stock

Donald A. Bergstrom, President, R&D at Relay Therapeutics (NASDAQ:RLAY), sold 8,660 shares of company stock for $162,028 on July 6, 2026, through a pre-arranged trading plan. This transaction occurred while Relay shares are near their 52-week high, following significant gains. De

Tone
Neutral 50/100
Event
Market update
Published
08 Jul 2026 21:10
Source
Investing.com
Stock Titan Direct company coverage

CFO at Relay Therapeutics (RLAY) sells shares under Rule 10b5-1 plan

Relay Therapeutics CFO Thomas Catinazzo sold 17,717 shares of common stock on July 6, 2026, generating $331,131 at a weighted average price of $18.69 per share. These transactions were pre-arranged under a Rule 10b5-1 trading plan adopted in October 2025. Following the sale, Cati

Tone
Negative 40/100
Event
Market update
Published
08 Jul 2026 21:10
Source
Stock Titan
Stock Titan Direct company coverage

Relay Therapeutics (RLAY) CEO trades shares, keeps over 615K direct holdings

Relay Therapeutics President and CEO Sanjiv Patel reported selling 48,199 shares of common stock at a weighted average price of $19.58 under a pre-established 10b5-1 trading plan. This transaction followed an acquisition of 3,056 shares through the company's Employee Stock Purcha

Tone
Negative 38/100
Event
Deals and strategy
Published
08 Jul 2026 21:10
Source
Stock Titan
Investing.com Direct company coverage

JPMorgan initiates Relay Therapeutics stock coverage with overweight rating

JPMorgan has initiated coverage on Relay Therapeutics Inc. (NASDAQ:RLAY) with an overweight rating and a $28 price target, citing its drug zovegalisib as a potential multi-indication growth driver with projected worldwide peak sales of approximately $8.3 billion. The stock, curre

Tone
Positive 74/100
Event
Analyst action
Published
08 Jul 2026 08:09
Source
Investing.com
Investing.com Canada Direct company coverage

Form 144 RELAY THERAPEUTICS INC For: 7 July By Investing.com

This article announces the filing of Form 144 for RELAY THERAPEUTICS INC on July 7. The filing is a standard requirement for insiders wishing to sell restricted or control securities. This brief update is relevant for investors tracking insider transactions and regulatory filings

Tone
Neutral 50/100
Event
Regulatory and legal
Published
07 Jul 2026 21:41
Source
Investing.com Canada
Investing.com Direct company coverage

Relay Therapeutics stock hits 52-week high at 19.97 USD

Relay Therapeutics stock recently hit a 52-week high of $19.97, reflecting a significant return of 432% over the past year and substantial gains year-to-date. This surge is supported by positive analyst ratings and recent plans to raise $450 million through stock offerings, indic

Tone
Positive 72/100
Event
Analyst action
Published
07 Jul 2026 15:41
Source
Investing.com
Investing.com Canada Direct company coverage

Relay Therapeutics stock hits 52-week high at 19.97 USD By Investing.com

Relay Therapeutics (RLAY) stock reached a new 52-week high of $19.97, reflecting a significant year-over-year return of 432%. Despite this surge, InvestingPro suggests the company may be overvalued relative to its Fair Value. The biotech company recently announced a $275 million

Tone
Positive 81/100
Event
Market update
Published
07 Jul 2026 14:40
Source
Investing.com Canada
TradingView Direct company coverage

Enterprise value to revenue forward of Relay Therapeutics, Inc. – NASDAQ:RLAY

The article provides a financial metric—enterprise value to revenue forward—for Relay Therapeutics, Inc., traded on NASDAQ under the symbol RLAY. It appears to be a stub or a data point from a financial platform, indicating a value without additional surrounding context or detail

Tone
Neutral 50/100
Event
Earnings
Published
07 Jul 2026 12:40
Source
TradingView
TradingView Direct company coverage

Price to sales forward of Relay Therapeutics, Inc. – NASDAQ:RLAY

This article provides financial information for Relay Therapeutics, Inc. (NASDAQ: RLAY), focusing on its forward price-to-sales ratio. It presents various financial data points and market information related to the company on the TradingView platform. The content is brief, primar

Tone
Neutral 50/100
Event
Market update
Published
07 Jul 2026 01:12
Source
TradingView
TradingView Direct company coverage

Price to book forward of Relay Therapeutics, Inc. – NASDAQ:RLAY

This article provides financial performance data for Relay Therapeutics, Inc. (NASDAQ: RLAY), specifically focusing on its forward price-to-book ratio. The content is hosted on TradingView, an investment analysis platform, indicating that the information is intended for investors

Tone
Neutral 50/100
Event
Market update
Published
03 Jul 2026 16:09
Source
TradingView
GuruFocus Direct company coverage

Insider Sell: Peter Rahmer Sells 50,000 Shares of Relay Therapeu

Peter Rahmer, an insider at Relay Therapeutics Inc (RLAY), sold 50,000 shares on June 30, 2026, and now holds 228,913 shares. Over the past year, Rahmer has sold 121,403 shares with no purchases, part of a company-wide trend of 22 insider sells and no buys. Shares traded at $19.0

Tone
Negative 28/100
Event
Market update
Published
03 Jul 2026 05:40
Source
GuruFocus
Stock Titan Direct company coverage

Relay Therapeutics (RLAY) exec ESPP buy, 50K-share 10b5-1 sale

Peter Rahmer, an executive at Relay Therapeutics (RLAY), reported both a sale and an acquisition of company stock on June 30, 2026. He sold 50,000 shares at a weighted average price of $19.09 under a pre-arranged Rule 10b5-1 trading plan and simultaneously acquired 3,056 shares a

Tone
Negative 39/100
Event
Deals and strategy
Published
02 Jul 2026 20:40
Source
Stock Titan
Stock Titan Direct company coverage

RLAY (NASDAQ: RLAY) Form 144: 50,000 Performance Stock Units; 753-share sale

A Form 144 filing for Relay Therapeutics (RLAY) reports the intent related to 50,000 Performance Stock Units (PSUs) dated January 29, 2025, and discloses a recent sale of 753 common shares on April 28, 2026, for $11,136.87. The filing is considered routine and administrative, pro

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 04:40
Source
Stock Titan
Simply Wall Street Direct company coverage

Relay Therapeutics (RLAY) Joins Multiple Russell Growth Indexes Is Its Biotech Role Being Repriced?

Relay Therapeutics (RLAY) has been added to several Russell growth indexes including the Russell 3000 Growth and Russell 2000 Growth. While this inclusion could increase visibility and liquidity, it doesn't alter the core investment narrative which is still centered on clinical p

Tone
Neutral 50/100
Event
Balance sheet
Published
01 Jul 2026 04:40
Source
Simply Wall Street
Market source Direct company coverage

Relay Therapeutics Insider Sale Tops $3 Million as Shares Surge 500% This Past Year

Relay Therapeutics CFO Thomas Catinazzo sold over $3 million in company stock after exercising options, a move explained by a Rule 10b5-1 trading plan and not a shift in strategy. Despite the sale, Catinazzo retains significant equity exposure through unexercised options. The com

Tone
Neutral 50/100
Event
Market update
Published
30 Jun 2026 00:39
Source
Market source